Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer

doi:10.1155/2022/1763778

	Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer
	Li, Yue 1; Li, Chong 2; Jiang, Ya 3; Han, Xue 3; Liu, Sisi 3; Xu, Xiuxiu 3; Tang, Wanxiangfu 3; Ou, Qiuxiang 3; Bao, Hua 3; Wu, Xue 3
刊名	JOURNAL OF ONCOLOGY
	2022-04-11
卷号	2022
ISSN号	1687-8450
DOI	10.1155/2022/1763778
通讯作者	Zhang, Yixiang(047601zhangyx@163.com) ; Wang, Yuezhen(yuezhenwang68@126.com)
英文摘要	Programmed cell death 1 ligand 1 (PD-L1) has been approved as predictive biomarker for non-small-cell lung cancer (NSCLC) patients treated with PD-(L)1 blockade therapy. The clinical/genomic features associated with PD-L1 are not well studied. Genomic profiling of tumor biopsies from 883 Chinese NSCLC patients was performed by targeted next-generation sequencing. Immunohistochemical analysis was conducted to evaluate PD-L1 expression levels using antibodies Dako 22C3 and 28-8, respectively. Our study showed distinct correlation between PD-L1 expression and clinical/genomic characteristics when using different PD-L1 antibodies and in different histological subtypes including adenocarcinoma (ADC) and squamous cell carcinoma (SCC), respectively. PD-L1 high expression (22C3) was associated with male and lymph node metastasis only in ADC patients. Furthermore, mutations of TP53 and KRAS, KIF5B-RET fusion, copy number gains of PD-L1 and PD-L2, and arm-level amplifications of chr.12p were significantly associated with PD-L1 positive status in ADC patients. For SCC patients, the gain of EGFR and MDM2 and loss of PTPRD were negatively associated with PD-L1 expression. We also compared our results with other studies and found conflicting results presumably because of the multiplicity of antibody clones and platforms, the difference of cutoffs for assigning PD-L1 expression levels, and the variation in study populations. Our study can help to understand the utility and validity of PD-L1 as biomarker of response to immune checkpoint inhibitors.
资助项目	Zhejiang Natural Science Foundation[20160171]
WOS关键词	MUTATIONS ; BLOCKADE ; LIGAND ; OVEREXPRESSION ; PEMBROLIZUMAB ; HETEROGENEITY ; ASSOCIATION ; ACTIVATION ; ASSAYS ; TP53
WOS研究方向	Oncology
语种	英语
出版者	HINDAWI LTD
WOS记录号	WOS:000806508500004
资助机构	Zhejiang Natural Science Foundation
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/131223]
专题	中国科学院合肥物质科学研究院
通讯作者	Zhang, Yixiang; Wang, Yuezhen
作者单位	1.Harbin Med Univ, Dept Med Oncol, Canc Hosp, Harbin 150081, Heilongjiang, Peoples R China 2.Soochow Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 3, Changzhou, Jiangsu, Peoples R China 3.Nanjing Geneseeq Technol Inc, Dept Res & Dev, Nanjing, Jiangsu, Peoples R China 4.Haining Peoples Hosp, Haining, Zhejiang, Peoples R China 5.Dalian Med Univ, Dept Thorac Surg, Affiliated Hosp 1, Dalian, Liaoning, Peoples R China 6.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Zhejiang, Peoples R China 7.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Li, Yue,Li, Chong,Jiang, Ya,et al. Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer[J]. JOURNAL OF ONCOLOGY,2022,2022.
APA	Li, Yue.,Li, Chong.,Jiang, Ya.,Han, Xue.,Liu, Sisi.,...&Wang, Yuezhen.(2022).Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer.JOURNAL OF ONCOLOGY,2022.
MLA	Li, Yue,et al."Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer".JOURNAL OF ONCOLOGY 2022(2022).